Lexogen GmbH

  • Funded by Austrian Research Promotion Agency (FFG)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    Austrian Research Promotion Agency (FFG)
  • Principal Investigator

    N/A

  • Research Location

    Austria
  • Lead Research Institution

    Lexogen GmbH
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The company's platform technology is to be adapted so that real mass screening is made possible using Next Generation Sequencing (NGS). At the same time, the mutation rate of the virus should be able to be tracked, which is of great importance for future epidemic predictions and vaccine development, and enables a differentiation from other pathogens that cause colds.